The Relationship Between the Use of 3-Month DMPA Injectable Contraception and the Incidence of Spotting among Contraception Users
DOI:
https://doi.org/10.53713/htechj.v4i1.578Keywords:
DMPA injectable contraception, spotting, family planning acceptors, contraceptionAbstract
The 3-month DMPA injectable contraceptive is widely used because of its effectiveness, convenience, and affordability. However, prolonged use may cause side effects, particularly menstrual disturbances such as spotting, which can affect user comfort and compliance. This study's aimed to analyze the association between the duration of 3-month DMPA injectable contraceptive use and the occurrence of spotting among family planning acceptors. This analytical cross-sectional study involved 30 family planning acceptors selected through purposive sampling. Data were collected using a structured questionnaire and analyzed using the Chi-square test with a significance level of 0.05. Among the 30 respondents, 66.7% had used the 3-month DMPA injectable contraceptive for 1–2 years, and 43.3% experienced spotting. Statistical analysis showed no significant association between the duration of 3-month DMPA use and spotting (p = 0.088). Spotting is a common side effect among users of the 3-month DMPA injectable contraceptive, but it is not significantly associated with the duration of use. Comprehensive counseling and education regarding potential side effects are essential to improve user comfort and contraceptive compliance.
References
Abukres, S. (2025). Real-World Effectiveness of Depot Medroxyprogesterone Acetate (DMPA): A Physician Survey on Failure Rates and Contributing Factors: Effectiveness of Depot Medroxyprogesterone Acetate (DMPA). Lebda Medical Journal, 10(1), 21-37. https://doi.org/10.65137/lmj.v10i1.226
Barretta, M., & Grandi, G. (2025). Understanding Problematic Bleeding During Contraceptive Use: Guidance for Clinicians. Open Access Journal of Contraception, 16, 131–145. https://doi.org/10.2147/OAJC.S431368
Bolaang, SG., Widia Shofa Ilmiah, & Rizful Maulina. (2025). Relationship between the Use of Hormonal Contraception and Spotting Incidents in the Sonuo Village Health Center Area. Proceedings International Conference of Innovation Science, Technology, Education, Children, And Health, 5(1), 94–103. https://doi.org/10.62951/icistech.v5i1.184
Castillo, K., Zambrano, K., Barba, D., Robayo, P., Sanon, S., Caicedo, A., & Jijon Chiriboga, A. J. (2022). Long-acting reversible contraceptives effects in abnormal uterine bleeding, a review of the physiology and management. European Journal of Obstetrics & Gynecology and Reproductive Biology, 270, 231-238. https://doi.org/10.1016/j.ejogrb.2022.01.020
Challa, S., Chiu, C., Jegede, A., Idiodi, I., Aliyu, M., Okoli, C., ... & Omoluabi, E. (2025). Quality of counseling for self-administering injectable contraception: field evidence from mystery client interactions in Lagos, Nigeria. BMC Women's Health, 25(Suppl 1), 399. https://doi.org/10.1186/s12905-025-03946-2
Coulson, J., Sharma, V., & Wen, H. (2023). Understanding the global dynamics of continuing unmet need for family planning and unintended pregnancy. China Population and Development Studies, 7(1), 1-14. https://doi.org/10.1007/s42379-023-00130-7
Creinin, M. D., Vieira, C. S., Westhoff, C. L., & Mansour, D. J. (2022). Recommendations for standardization of bleeding data analyses in contraceptive studies. Contraception, 112, 14-22. https://doi.org/10.1016/j.contraception.2022.05.011
Durante, J. C., Sims, J., Jarin, J., Gold, M. A., Messiah, S. E., & Francis, J. K. (2023). Long-Acting Reversible Contraception for Adolescents: A Review of Practices to Support Better Communication, Counseling, and Adherence. Adolescent Health, Medicine and Therapeutics, 14, 97–114. https://doi.org/10.2147/AHMT.S374268
Erlank, C.P., Ali, G., Birhanu, F., Stanley, M., Chirwa, J. S., Kachale, F., & Gunda, A. (2023). Health care provider and client experiences of counselling on depot medroxyprogesterone acetate subcutaneous (DMPA-SC) for self-injection in Malawi. PLOS Global Public Health, 3(11), e0002057. https://doi.org/10.1371/journal.pgph.0002057
Feriani, P., Yunitasari, E., Efendi, F., Krisnana, I., Ernawati, R., Tianingrum, N. A., & Safaah, N. (2024). A Systematic Review of Determinants Influencing Family Planning and Contraceptive Use. Iranian Journal of Nursing and Midwifery Research, 29(5), 596–607. https://doi.org/10.4103/ijnmr.ijnmr_321_23
Hafid, R. N. H. (2025). Family Planning, Population Growth and Social Welfare: A Qualitative Study. Advances in Healthcare Research, 3(2), 119–131. https://doi.org/10.60079/ahr.v3i2.489
Martell, S., Marini, C., Kondas, C. A., & Deutch, A. B. (2023). Psychological side effects of hormonal contraception: a disconnect between patients and providers. Contraception and Reproductive Medicine, 8(1), 9. https://doi.org/10.1186/s40834-022-00204-w
Monica, L. P., Ulfa, M., & Fata, U. H. (2024). Menstrual Disorders of 3-Month Contraceptive Injection Acceptors in Independent Midwife Practice in Binangun District, Blitar Regency. Jurnal Ners Dan Kebidanan (Journal of Ners and Midwifery), 11(3), 312–321. https://doi.org/10.26699/jnk.v11i3.ART.p312-321
Purwoko, E., Arief, H., Radiwan, R., Prasetya, L. K. B., Zuhdi, A., Wibowo, H., ... & Arifin, H. (2025). Use of intrauterine devices/implants and injectables under the universal health coverage scheme in Indonesia. British Journal of Midwifery, 33(6), 333-341. https://doi.org/10.12968/bjom.2024.0087
Rachman, AB., Sulistiawati, & Ratna Dwi Jayanti. (2025). Differences in the Incidence of Anemia in Acceptors of 1-Month Injection and 3-Month Injection Contraceptives. Professional Health Journal, 7(1), 33–42. https://doi.org/10.54832/phj.v7i1.954
Rajaraman, R., Vaithilingan, S., & Selvavinayagam, T. S. (2024). Acceptance, Adherence, and Side Effects of Depot Medroxyprogesterone Acetate: A Prospective Observational Study. Cureus, 16(4), e58700. https://doi.org/10.7759/cureus.58700
Rizkianti, A., Kistiana, S., Fajarningtiyas, D. N., Hutasoit, E. F., Baskoro, A. A., Maryani, H., ... & Muthmainnah, M. (2024). Understanding the association between family planning and fertility reduction in Southeast Asia: a scoping review. BMJ open, 14(6), e083241. https://doi.org/10.1136/bmjopen-2023-083241
Saadah, N., Mahendra, F. G., Usnawati, N., & Surtinah, N. (2023). Duration of Use of KB Injections 3 Months Against Spotting Events in KB Participants. International Journal of Advanced Health Science and Technology, 3(4), 241-245. https://doi.org/10.35882/ijahst.v3i4.266
Shaheen, K., Kamel, H. H., Mostafa Mohammed, E., Hashim Mohammed, A., Ahmed Sileem, S., Fouad, M., Shehata Sayd, Z., & ElHodiby, M. E. (2024). Clomiphene citrate as a new modality in management of vaginal bleeding with depomedroxyprogesterone acetate (DMPA): A randomized controlled trial. Steroids, 206, 109425. https://doi.org/10.1016/j.steroids.2024.109425
Widayanti, C., Nila Widya Keswara, & Anik Sri Purwanti. (2024). The Relationship between Long-Time Use of Injectable Contraception Devices (3 Months Depo Medroxyprogesterone Acetate) and Libido Change in Family Planning Acceptors. Health and Technology Journal (HTechJ), 2(4), 328–333. https://doi.org/10.53713/htechj.v2i4.207
